Therefore, CD37 seems to be an appropriate therapeutic target in patients with relapsed B-cell derived malignancies, such as B-cell CLL, hairy-cell leukemia (HCL) and B-cell NHL. The gene discussed is CD37; the disease is B-cell chronic lymphocytic leukemia.